Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
1. A method of treating a disease selected from allograft rejection and graft versus host disease in a patient in need thereof, comprising administering to the patient a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the disease is graft versus host disease.
4. The method of claim 3 , wherein about 5 to about 1000 mg of the compound, or pharmaceutically acceptable salt thereof, is administered to the patient.
5. The method of claim 3 , further comprising administering to the patient at least one additional therapeutic agent.
6. The method of claim 5 , wherein the therapeutic agent is administered to a patient simultaneously or sequentially.
7. The method of claim 5 , wherein said therapeutic agent is an immunosuppressant.
8. The method of claim 5 , wherein said therapeutic agent is a steroid.
9. The method of claim 5 , wherein said therapeutic agent is a corticosteroid.
10. The method of claim 9 , wherein said corticosteroid is dexamethasone or prednisone.
11. The method of claim 9 , wherein said corticosteroid is dexamethasone.
12. The method of claim 9 , wherein said corticosteroid is prednisone.
13. The method of claim 2 , wherein the disease is allograft rejection.
14. The method of claim 13 , wherein about 5 to about 1000 mg of the compound, or pharmaceutically acceptable salt thereof, is administered to the patient.
15. The method of claim 13 , further comprising administering to the patient at least one additional therapeutic agent.
16. The method of claim 15 , wherein the therapeutic agent is administered to a patient simultaneously or sequentially.
17. The method of claim 15 , wherein said therapeutic agent is an immunosuppressant.
18. The method of claim 15 , wherein said therapeutic agent is a steroid.
19. The method of claim 15 , wherein said therapeutic agent is a corticosteroid.
20. The method of claim 19 , wherein said corticosteroid is dexamethasone or prednisone.
21. The method of claim 19 , wherein said corticosteroid is dexamethasone.
22. The method of claim 19 , wherein said corticosteroid is prednisone.
23. A method of treating a disease selected from allograft rejection and graft versus host disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
24. The method of claim 23 , wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
25. The method of claim 24 , wherein the pharmaceutical composition is suitable for oral administration.
26. The method of claim 25 , wherein the pharmaceutical composition is in tablet form.
27. The method of claim 26 , wherein the disease is graft versus host disease.
28. The method of claim 26 , wherein the disease is allograft rejection.
29. The method of claim 24 , wherein the disease is graft versus host disease.
30. The method of claim 24 , wherein the disease is allograft rejection.